Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Biopharma Biotech Business Development
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Commercialization Consulting Resource Center
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
Biopharma Commercialization FDA
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies
Biopharma Commercialization Consulting Resource Center

Biopharma

PBM GPO market share shifts as health plan enrollment continues to churn PBM GPO market share shifts as health plan enrollment continues to churn
Blog December 11, 2024
PBM GPO market share shifts as health plan enrollment continues to churn
Drug combinations: your questions answered Drug combinations: your questions answered
Blog November 19, 2024
Drug combinations: your questions answered
How the U.S. election could impact the healthcare industries How the U.S. election could impact the healthcare industries
Blog October 17, 2024
How the U.S. election could impact the healthcare industries
Increasing your likelihood of success in dealmaking discussions Increasing your likelihood of success in dealmaking discussions
Blog October 17, 2024
Increasing your likelihood of success in dealmaking discussions
Beyond animal testing: the rise of organs-on-chips technology Beyond animal testing: the rise of organs-on-chips technology
Blog October 7, 2024
Beyond animal testing: the rise of organs-on-chips technology
Biotech financing’s rebound: How high will it go? Biotech financing’s rebound: How high will it go?
Blog September 17, 2024
Biotech financing’s rebound: How high will it go?
Early diagnosis in Alzheimer’s disease: A first step towards better care Early diagnosis in Alzheimer’s disease: A first step towards better care
Blog September 11, 2024
Early diagnosis in Alzheimer’s disease: A first step towards better care
Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts
Blog September 5, 2024
Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts
After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient
Blog August 28, 2024
After loss of exclusivity, small-molecule generics bite quick and hard, while biologics remain resilient
CMS enters drug price negotiation arena in sea change for industry CMS enters drug price negotiation arena in sea change for industry
Blog August 20, 2024
CMS enters drug price negotiation arena in sea change for industry